A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
Authors
Keywords
Signal transduction inhibitor, Chemo-resistance, Clinical trial, Dose-escalation
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-05-16
DOI
10.1007/s10637-018-0588-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
- (2017) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
- (2016) Matthew Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
- (2016) Tony Shu Kam Mok et al. Journal of Thoracic Oncology
- P-118 * Tepotinib (MSC2156119J) monotherapy in patients with MET-positive advanced hepatocellular carcinoma with Child-Pugh Class A liver function who have failed sorafenib treatment: phase Ib/II trial
- (2015) S. Faivre et al. ANNALS OF ONCOLOGY
- The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
- (2015) M. P. Lolkema et al. CLINICAL CANCER RESEARCH
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects
- (2015) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
- (2014) L. R. Molife et al. CLINICAL CANCER RESEARCH
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
- (2014) Christiane R. Maroun et al. PHARMACOLOGY & THERAPEUTICS
- Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
- (2013) J. Jean Cui JOURNAL OF MEDICINAL CHEMISTRY
- RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses
- (2013) Henok Eyob et al. OncoImmunology
- Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET
- (2012) Jeffrey R. Infante et al. INVESTIGATIONAL NEW DRUGS
- Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
- (2012) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract A193: Assessment of effect of low- and high-fat diet on E7050 pharmacokinetics and characterization of E7050 pharmacokinetics after 100 mg, 200 mg, and 400 mg single oral doses in healthy subjects.
- (2012) B. Mistry et al. MOLECULAR CANCER THERAPEUTICS
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
- (2009) Gretchen M. Schroeder et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now